Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Arcus Biosciences, Inc. amended credit facility of $150.0 million term loan commitments with Hercules Capital, Inc. maturing September 1, 2030.
- Instrument
- credit facility
- Principal
- $150.0 million term loan commitments
- Counterparty
- Hercules Capital, Inc.
- Maturity
- September 1, 2030
- Event
- amendment
Exact text from the filing
Agreement, dated as of August 27, 2024, by and among the Company, Hercules and the Lenders (the “Loan Agreement”). The First Amendment amends the terms for the remaining $150.0 million term loan commitments available under the loan facility such that, subject to customary terms and conditions, (a) $25.0 million is available at the Company's sole option through
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcus Biosciences, Inc. amended First Amendment to the Loan and Security Agreement with Hercules Capital, Inc. valued at $150.0 million (effective 2025-12-18).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Value
- $150.0 million
- Effective
- 2025-12-18
Exact text from the filing
On December 18, 2025 (the “Closing Date”), Arcus Biosciences, Inc. (the “Company”) entered into a First Amendment to the Loan and Security Agreement (the “First Amendment”) with the several banks and other financial institutions or entities party thereto (the “Lenders”), as lenders, and Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent.
View on SEC.gov